So this is a bill that's a good interim measure. As I said earlier, it obviously does have some shortcomings. Specifically, it doesn't provide sufficient detail on a few important issues: it certainly doesn't provide sufficient detail on frequency of testing, it doesn't really provide sufficient detail on how to ensure that quality control during manufacturing, and it doesn't really provide sufficient detail on the role that accredited labs will play throughout this sort of process. But the therapeutic products bill, as Mr Muller pointed out, will provide a much more comprehensive and a much more robust framework that will cover the regulation of sunscreen products, and we very much look forward to the introduction and look forward to the progression of that particular piece of legislation.